Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €53.58 EUR
Change Today +0.02 / 0.04%
Volume 552.5K
FRE On Other Exchanges
As of 8:44 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

fresenius se & co kgaa (FRE) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - €57.62
52 Week Low
05/6/14 - €34.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FRESENIUS SE & CO KGAA (FRE)

Related News

No related news articles were found.

fresenius se & co kgaa (FRE) Related Businessweek News

No Related Businessweek News Found

fresenius se & co kgaa (FRE) Details

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment provides products for hemodialysis and peritoneal dialysis. This segment offers dialyzers, dialysis machines, and renal pharmaceuticals, as well as dialysis- related services. As of December 31, 2014, it treated approximately 285,312 patients at 3,361 dialysis clinics. The Fresenius Kabi segment provides therapy and care for chronically and critically ill patients. This segment offers intravenously administered generic drugs, such as anesthetics, anti-infectives, and analgesics, as well as drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps; products used in the collection and processing whole blood and blood components, as well as in transfusion medicine. The Fresenius Helios segment operated approximately 110 hospitals, including 86 acute care hospitals and 24 post acute care clinics; 47 outpatient clinics; and 15 nursing homes. The Fresenius Vamed manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as provides maintenance, technical, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg, Germany.

216,275 Employees
Last Reported Date: 03/19/15
Founded in 1912

fresenius se & co kgaa (FRE) Top Compensated Officers

Chairman of the Management Board - Fresenius ...
Total Annual Compensation: €2.4M
Chief Financial Officer of Fresenius Manageme...
Total Annual Compensation: €1.5M
Chief Executive Officer of Fresenius Kabi
Total Annual Compensation: --
Chief Legal & Compliance Officer of Fresenius...
Total Annual Compensation: €1.1M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €2.9M
Compensation as of Fiscal Year 2014.

fresenius se & co kgaa (FRE) Key Developments

Fresenius Reports Earnings Results for the First Quarter of 2015

Fresenius reported earnings results for the first quarter of 2015. For the period, the company achieved sales of EUR 6,483,000,000, EBITDA of EUR 851 million and net income of EUR 292 million. The absolute level of sales and net income and the solid double-digit growth rates in constant currency and actual currency rates made this one of most successful quarters ever. EBIT reached EUR 851 million, up 18% year-on-year at constant currency. Net income reached EUR 292 million, so 16% increase at constant currency.

Fresenius SE & Co KGaA Raises Earnings Guidance for the Year 2015

Fresenius SE & Co KGaA raised earnings guidance for the year 2015. The company now expected net income growth of 13% to 16% in constant currency. Previously, the company expected net income growth of 9% to 12% in constant currency. The company fully confirms its Group sales guidance. Sales are expected to increase by 7% to 10% in constant currency.

Fresenius Seeks Acquisitions

Fresenius SE & Co KGaA (DB:FRE) said that company will continue to look for large acquisitions once the current M&A wave is over.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRE:GR €53.58 EUR +0.02

FRE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.65 USD -0.29
Danone SA €64.33 EUR +0.65
DaVita HealthCare Partners Inc $81.51 USD -0.83
Hospira Inc $87.71 USD -0.02
Mead Johnson Nutrition Co $97.05 USD +0.31
View Industry Companies

Industry Analysis


Industry Average

Valuation FRE Industry Range
Price/Earnings 26.0x
Price/Sales 1.2x
Price/Book 3.0x
Price/Cash Flow 26.0x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS SE & CO KGAA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at